Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 10/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22793144 | 0.93 | MAOA (0.50) | TAAR1MAOAPNMTSIGMAR1 | |
| SCHEMBL9583996 | 0.89 | TAAR1 (0.57) | TAAR1MAOACYP2A6PNMTHTR6 | |
| SCHEMBL3173093 | 0.86 | TAAR1 (0.42) | TAAR1MAOACYP2A6PNMTHTR6 | |
| SCHEMBL10236635 | 0.85 | TAAR1 (0.44) | TAAR1MAOACYP2A6HTR6DRD2 | |
| SCHEMBL422194 | 0.84 | MAOA (0.58) | TAAR1MAOACYP2A6HTR6DRD2 | |
| Isobutylbenzene SCHEMBL28380771 | 0.83 | MAOA (0.61) | TAAR1MAOACYP2A6SLC6A2SLC6A4 | |
| SCHEMBL3030292 | 0.83 | LPL (0.46) | — | |
| SCHEMBL8539519 | 0.82 | GABRA1 (0.50) | TAAR1MAOACYP2A6PNMTSLC6A2 | |
| SCHEMBL22793495 | 0.81 | PNMT (0.39) | TAAR1MAOACYP2A6PNMTSLC6A2 | |
| SCHEMBL1680442 | 0.80 | PNMT (0.48) | TAAR1MAOACYP2A6PNMTSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389771-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8299307-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120004269-A1 | Alkynyl Phenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20090203708-A1 | NOVEL SUBSTITUTED-1-H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-08-13 | — | — | US | disclosed |
| EP-2035406-A4 | NOVEL SUBSTITUTED-1H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RES INST CHEM TECH (KR) | 2009-08-05 | — | — | EP | disclosed |
| EP-2035406-A1 | NOVEL SUBSTITUTED-1H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Korea Research Institute of Chemical Technology (KR) | 2009-03-18 | — | — | EP | disclosed |
| US-20090062353-A1 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. | 2009-03-05 | — | — | US | disclosed |
| WO-2009005794-A2 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008004716-A1 | NOVEL SUBSTITUTED-1H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESERACH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062353-A1 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | PDE6D, STARD3, PDE6C | TAAR1 4217/4885MAOA 2356/4885CYP2A6 2921/4885 |
| US-20120004269-A1 | Alkynyl Phenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | PDE6D, STARD3, PDE6C | TAAR1 4217/4885MAOA 2356/4885CYP2A6 2921/4885 |
| US-20090203708-A1 | NOVEL SUBSTITUTED-1-H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | HTR5A, HTR3B, HTR1A | TAAR1 123/4885MAOA 92/4885CYP2A6 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.